- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02055339
Pilot Study Comparing Different Modes of Non-invasive Ventilation for the Oral Feeding of Preterm Infants (CHOMP)
Comparison of Nasal Continuous Positive Airway Pressure With Low Flow Oxygen Versus Heated, Humidified High Flow Nasal Cannula for Oral Feeding of the Premature Infant (CHOMP Trial): A Pilot Study
Study Overview
Status
Conditions
Detailed Description
The primary objective of this study is to assess whether a baby born at less than 28 weeks gestation who at 34 weeks corrected gestational age, will reach full oral feeds faster on the current practice of nasal continuous positive airway pressure (nCPAP) and low flow oxygen (LFO2) or the new intervention of heated, humidified high flow nasal cannula (HHHFNC).
The specific aim of this study is to investigate the effectiveness and safety of using nCPAP and LFO2 versus HHHFNC for reaching full oral feeds in premature infants.
We hypothesize that the use of HHHFNC at the initiation of oral feeding will allow babies to reach full feeds sooner as compared with nCPAP and LFO2.
Babies born at extreme prematurity (<28 weeks gestation), are at risk of chronic lung disease due to lung immaturity. A proportion of preterm infants remains dependent on non-invasive ventilation at the corrected gestational age when they are at the neurodevelopmental stage of oral feeds. If oral feeds are not initiated in a timely manner, delays in progression of oral feeds and oral aversion may occur, resulting in longer hospital stays and/or gastrostomy tube insertions. Those that are nCPAP dependant are unable to orally feed due to safety concerns so are placed on a low pressure system of low flow nasal cannula during feeds. This may lead to microatelectasis in those babies needing a higher pressure to maintain gas exchange. HHHFNC is another method of non-invasive ventilation and it can be changed from a high pressure system (in litres per minute) to a low pressure system by turning a dial, and not having to disconnect the baby from the respiratory system.
Randomized controlled trial consisting of two arms: 1) The CPAP/LFO2 arm in which the babies will be maintained on nCPAP until the time of oral feeds wherein they will have their circuits exchanged for a low flow cannula. 2) The HHHFNC arm in which babies will be maintained on 5 lpm of HHHFNC until the time of oral feeds, wherein they will have their flows turned down to 2 lpm. The study will be conducted in a level III neonatal intensive care unit (NICU) in Mount Sinai hospital. The study subjects are 40 preterm babies that were born before 28 weeks gestational age who are now 34 weeks corrected gestational age (CGA), which are dependent on non-invasive ventilation and are receiving full feeds via nasogastric tube. The randomization will occur at 33+6/7 weeks CGA. Demographic characteristics will be compared between groups using Chi-square test or Fisher's exact test for categorical variables. Differences between continuous variables will be assessed using Student's t-test or Mann-Whitney U test for non-normally distributed variables. The primary outcome (time to full oral feeds) is a binary outcome and will be compared between groups using Chi-square test or Fisher's exact test. A difference of a p-value of <0.05 will be considered significant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Mount Sinai Hospital NICU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age of <28 weeks (24+0 to 27+6) with corrected gestational age of 34 weeks
- Neonates requiring respiratory support in the form of nCPAP or HHHFNC at any pressure at 34 weeks corrected gestational age and failing a trial of low flow oxygen or room air
- Full enteral feeding tolerated through a nasogastric tube
Exclusion Criteria:
- Gestational age > 28 weeks
- Neonate requiring biphasic nCPAP
- Mother never at the bedside and no consent for bottle feeds
- Severe nasal breakdown or genetic/neurologic abnormalities which impair oral feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fisher & Paykel heated humidified high flow nasal cannula
For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization.
When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm.
The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
|
|
Active Comparator: InfantFlow/RAM nasal continuous positive airway pressure
Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart.
The nCPAP circuit will only be removed when it is time for oral feeds.
The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations.
The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to reach full oral feeds
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time on non-invasive ventilation or oxygen
Time Frame: 2 months
|
2 months
|
Occurrence of feeding intolerance or reflux
Time Frame: 2 months
|
2 months
|
Occurrence of apneas/bradycardias/desaturations above baseline
Time Frame: 2 months
|
2 months
|
Weight gain
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sandra Leibel, MD, Mount Sinai Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MountSinaiH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lung Disease
-
Sygehus LillebaeltDanmarks Lungeforening; Chiesi Foundation; Overlæge Jørgen Werner Schous og hustru...Active, not recruitingChronic Obstructive Pulmonary DiseaseDenmark
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Centre Hospitalier Intercommunal CreteilRecruitingChronic Obstructive Pulmonary Disease | Chronic Obstructive Lung DiseaseFrance
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Aveiro UniversityPrograma Operacional Inclusão Social e Emprego (POISE); Programa Operacional... and other collaboratorsCompletedLung Diseases | Chronic Obstructive Pulmonary Disease | Pulmonary Disease | Interstitial Lung Disease | Chronic Respiratory DiseasePortugal
-
Icahn School of Medicine at Mount SinaiUniversity of Pittsburgh; Brigham and Women's Hospital; University of New Mexico and other collaboratorsActive, not recruitingLung Cancer | Interstitial Lung Disease | Chronic Airway DiseaseUnited States
-
Beni-Suef UniversityCompleted
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Lung Disease (n=10) | Interstitial Lung Disease (n=10)Germany
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
Clinical Trials on Fisher & Paykel heated humidified high flow nasal cannula
-
Tufts Medical CenterVirginia Commonwealth UniversityActive, not recruitingChronic Obstructive Pulmonary Disease | COPD Exacerbation | Airflow ObstructionUnited States
-
University Hospital, Clermont-FerrandCompletedPostoperative HypoxemiaFrance
-
Children's Hospital Los AngelesCompletedHigh Flow Nasal CannulaUnited States
-
Mayo ClinicCompletedObstructive Sleep ApneaUnited States
-
McMaster UniversityFisher and Paykel HealthcareActive, not recruiting
-
Frank C SciurbaFisher and Paykel HealthcareCompleted
-
Zekai Tahir Burak Women's Health Research and Education...UnknownPrematurity | Extubation Failure
-
Hamad Medical CorporationSidra Medical and Research CenterRecruitingBronchiolitis | Respiratory Syncytial Virus (RSV)Qatar
-
Ashford and St. Peter's Hospitals NHS TrustCompletedPremature BirthUnited Kingdom
-
Shin Kong Wu Ho-Su Memorial HospitalFu Jen Catholic UniversityCompleted